141 related articles for article (PubMed ID: 16273042)
1. An impossible job.
Nat Biotechnol; 2005 Nov; 23(11):1321. PubMed ID: 16273042
[No Abstract] [Full Text] [Related]
2. Pessimistic response to FDA leadership change.
Kling J
Nat Biotechnol; 2005 Nov; 23(11):1325. PubMed ID: 16273044
[No Abstract] [Full Text] [Related]
3. The big gap at the FDA.
Stipp D
Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
[No Abstract] [Full Text] [Related]
4. Mission: promoting, protecting the public health. FDA Commissioner Mark B. McClellan. Interview by Ray Formanek Jr.
McClellan MB
FDA Consum; 2003; 37(2):12-7. PubMed ID: 12715764
[No Abstract] [Full Text] [Related]
5. The special treatment.
Osborne R
Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
[No Abstract] [Full Text] [Related]
6. Off-label promotion.
Somberg J
Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
[No Abstract] [Full Text] [Related]
7. IL-1 trap go-ahead.
Ratner M
Nat Biotechnol; 2008 May; 26(5):485. PubMed ID: 18464767
[No Abstract] [Full Text] [Related]
8. 2006 drug approvals: finding the niche.
Owens J
Nat Rev Drug Discov; 2007 Feb; 6(2):99-101. PubMed ID: 17342860
[No Abstract] [Full Text] [Related]
9. A merger too far?
Wadman M
Nature; 2007 Mar; 446(7131):15. PubMed ID: 17330017
[No Abstract] [Full Text] [Related]
10. A changing drug supply.
Nature; 2007 Feb; 445(7127):460. PubMed ID: 17268432
[No Abstract] [Full Text] [Related]
11. New therapies from old medicines.
Chen ST; Dou J; Temple R; Agarwal R; Wu KM; Walker S
Nat Biotechnol; 2008 Oct; 26(10):1077-83. PubMed ID: 18846070
[No Abstract] [Full Text] [Related]
12. Sandoz sues FDA over delay in first biogeneric approval.
Fox JL
Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
[No Abstract] [Full Text] [Related]
13. Study reveals secrets to faster drug development.
Frantz S
Nat Rev Drug Discov; 2006 Nov; 5(11):883. PubMed ID: 17117519
[No Abstract] [Full Text] [Related]
14. Commentary: Epidemiology and the pharmaceutical industry: an inside perspective.
Haas J
Int J Epidemiol; 2008 Feb; 37(1):53-5; discussion 65-8. PubMed ID: 18184672
[No Abstract] [Full Text] [Related]
15. Vioxx, radiology, and the Food and Drug Administration.
Pentecost MJ
J Am Coll Radiol; 2005 May; 2(5):394-7. PubMed ID: 17411841
[No Abstract] [Full Text] [Related]
16. Optimer resurrects C. difficile antibiotic to win approval.
Fox JL
Nat Biotechnol; 2011 Jul; 29(7):557-8. PubMed ID: 21747365
[No Abstract] [Full Text] [Related]
17. Concerns raised over declining antiinfectives R&D.
Fox JL
Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
[No Abstract] [Full Text] [Related]
18. Lack of new antibiotics refuted by recent study.
Scott L
Mod Healthc; 1994 Aug; 24(32):144. PubMed ID: 10135371
[No Abstract] [Full Text] [Related]
19. New drug approvals for 2002.
Frantz S; Smith A
Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
[No Abstract] [Full Text] [Related]
20. Market watch: key clinical and regulatory events in Q2 2010.
Hay M
Nat Rev Drug Discov; 2010 Apr; 9(4):261. PubMed ID: 20357797
[No Abstract] [Full Text] [Related]
[Next] [New Search]
